

Our Portfolio

Our broad portfolio of cancer-focused projects spans therapeutics, vaccines, diagnostics, medical devices, software and AI.
As the second biggest oncology out-licensor globally, and with exclusive rights to over £400 million of world-class cancer research each year, we're a powerful partner in the fight to conquer cancer.